Lenalidomide after stem-cell transplantation for multiple myeloma.

The New England Journal of Medicine
Philip L McCarthyCharles Linker

Abstract

Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide ...Continue Reading

References

Jan 1, 1970·Scandinavian Journal of Haematology·E Andersen, A Videbaek
Nov 19, 1970·The New England Journal of Medicine·R A KyleE D Bayrd
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Jan 6, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Fritz, H Ludwig
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Jul 25, 2007·Nature Reviews. Cancer·Teru HideshimaKenneth C Anderson
Aug 2, 2008·Blood·Bruno PaivaUNKNOWN GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Grou
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SpencerNola Kennedy
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Luc HarousseauPhilippe Moreau
Oct 29, 2009·Blood·A Keith StewartJesus F San-Miguel
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboMario Boccadoro
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco LadettoAntonio Palumbo
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Apr 13, 2011·Blood·Joaquin Martinez-LopezUNKNOWN Programa para el Estudio de la Terapé utica en Hemopatía Maligna
Oct 25, 2011·Blood·Gareth J MorganUNKNOWN National Cancer Research Institute Haematological Oncology Clinical Studies Group
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators

❮ Previous
Next ❯

Citations

Nov 28, 2012·Annals of Hematology·Chor Sang ChimWai Ki Lee
Oct 26, 2013·Current Hematologic Malignancy Reports·Jordan Schecter, Suzanne Lentzsch
Mar 12, 2013·International Journal of Hematology·Reiko WatanabeMasahiro Kizaki
Oct 1, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Isabelle Vande Broek, Peter Jacobs
Jun 6, 2012·Nature Reviews. Clinical Oncology·S Vincent Rajkumar
Mar 27, 2013·Nature Reviews. Clinical Oncology·Lois B TravisAndrea K Ng
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J L Harousseau
Aug 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Working Group
Jan 8, 2013·Japanese Journal of Clinical Oncology·Kenshi Suzuki
Oct 20, 2012·Current Opinion in Oncology·Margarita Blanes, Javier de la Rubia
Dec 6, 2012·Experimental Hematology & Oncology·Tahir LatifSaad Z Usmani
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David E Gerber, Joan H Schiller
Sep 8, 2012·Cancer Management and Research·Niels Wcj van de DonkKenneth C Anderson
Dec 4, 2012·Mediterranean Journal of Hematology and Infectious Diseases·P TosiG Visani
Feb 7, 2013·Oman Medical Journal·Khalil Al-Farsi
Nov 29, 2013·International Journal of Hematologic Oncology·Jagoda K Jasielec, Andrzej J Jakubowiak
Aug 25, 2012·Stem Cells International·Joel Sng, Thomas Lufkin
Jul 11, 2013·Future Oncology·Peter A Forsberg, Tomer M Mark
Nov 19, 2013·Journal of Comparative Effectiveness Research·Boris FreidlinEdward L Korn
Dec 3, 2013·International Journal of Clinical Pharmacy·Michelle A King, Rebecca L Pryce
Nov 8, 2012·Future Oncology·Alessandra LaroccaAntonio Palumbo
May 23, 2014·Der Radiologe·E K Mai, H Goldschmidt

❮ Previous
Next ❯